8 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
10 July 2025 - NICE has published final evidence-based recommendations on the use of zanubrutinib for the treatment of adults ...
10 July 2025 - New indication based on results of RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival. ...
11 July 2025 - New PDUFA action date of 13 December 2025. ...
10 July 2025 - Company planning to initiate Phase 3 program. ...
9 July 2025 - Eli Lilly Canada is pleased to announce that Zepbound KwikPen (tirzepatide injection) is now available in Canada, ...
8 July 2025 - Norgine is pleased to announce that Swissmedic has approved the registration of Ifinwil (eflornithine) as monotherapy ...
9 July 2025 - Trethera announced today that the US FDA has granted fast track designation for its novel drug, TRE-515, ...
8 July 2025 - The MHRA has today become the first regulator in the world to approve elinzanetant (Lynkuet) for the ...
9 July 2025 - Donald Trump’s move to ramp up tariffs on medicines and copper has sparked alarm among government ...
9 July 2025 - The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding ...
8 July 2025 - Novo Nordisk today announced the submission of an application to the EMA for approval of a new, ...
8 July 2025 - Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in ...
9 July 2025 - The threat of global 200 per cent tariffs on pharmaceutical products presents a challenge to Australia’s drug ...
7 March 2025 - The Pharmaceutical Reimbursement Review Committee has made mixed decisions on the two medicines for paroxysmal nocturnal ...